MeMed’s ImmunoXpert Device Set To Alleviate the Global Misuse of Antibiotics

23 April 2017

Blank
MeMed Ltd confirmed earlier this month that they had been awarded $9.2m by the US Department of Defence to develop its second-generation point-of-care test, to distinguish between bacterial and viral infections. The Israel-based start-up has called the device the ImmunoXpert, and it could play a key role in helping to alleviate the global misuse of antibiotics.

The ImmunoXpert test works by measuring proprietary immune system biomarkers with pattern recognition algorithms to accurately distinguish between viral and bacterial infections.

The device can provide a result within 15 minutes and MeMed's co-founder Kfir Oved stated that the device ‘’could differentiate between bacterial and viral infection with a sensitivity and accuracy of over 90%.”

It’s always great news to hear when a start-up gets funding and it’s a real grab that MeMed managed to get such a high profile and prolific grant.

The ImmunoXpert is not yet available in the US but has already been approved for use in the EU (CE-IVD certified), Switzerland and Israel.

Why is this device so important?
People are overusing antibiotics to cure common illnesses, in many cases when the problem is viral; not bacterial. With the antibacterial drugs market expected to top $45B globally by 2019, it’s easy to see how and why. The problem is, the overuse of antibiotics can render them ineffective meaning that future illnesses or infections that require vital or lifesaving antibiotic drug treatment could be ineffective on the patient.

Facts and Figures
MeMed's studies across the USA, China and the EU, suggest that the number of people on unnecessary antibiotic prescriptions is about $11bn. The cost to prescribe people who don’t need it is about $146bn and the number of patients infected with antibiotic-resistant bacteria is about $108m.

People don’t become immune to antibiotics…..bacteria do!
It’s a common misconception that people become immune to antibiotics. It’s not the people but the bacteria responsible for infections that become resistant. We take antibiotics to impede or kill the growth of bacteria to stop an infection. However, bacteria have been around for millennia and lived through aggressive environments, learning to adapt and survive against anything that could stunt their development or evolution for thousands of years.

Will MedMed’s ImmunoXpert be a turning point in the fight against mitigating the misuse of antibiotics? We’ll keep you posted!

Nicola Lawler, Projectus Consulting.

Projectus are the world leader in medical technology talent management. If you are currently hiring or looking for a new opportunity yourself, give us a call to explore what options are available for you today on 02038000501 or email cv@projectusconsulting.com.Projectus are the world leader in medical technology talent management. If you are currently hiring or looking for a new opportunity yourself, give us a call to explore what options are available for you today on 02038000501 or email cv@projectusconsulting.com.
Change your life today.

R&D | Engineering | Regulatory | Sales | Marketing | Clinical | Service